晚期心力衰竭患者长期机械支持下的心肌恢复生物学
本文综述长期机械循环支持(MCS)在晚期心力衰竭儿童和成人患者中通过心室机械卸载和有效血流动力学支持实现心脏逆重构和心肌恢复的生物学机制。MCS研究环境提供人类组织,推动「床旁到实验台再返回床旁」的转化研究,揭示心肌恢复通路并用于潜在治疗药物开发。
要点
- 心脏重构是初始心肌损伤后的适应性代偿过程,可逐渐变为适应不良并导致临床恶化和慢性心力衰竭。
- 长期MCS通过心室机械卸载和有效血流动力学支持,引起功能性、结构性、细胞和分子改变,即心脏逆重构。
- MCS研究环境提供人类组织,推动体外和体内小动物模型机制研究,揭示心肌恢复通路并用于潜在治疗药物开发。
核心结论
- 心脏重构和慢性心力衰竭并非必然导致静态终末期表型,至少可部分逆转。
- MCS介导的逆重构和心肌恢复生物学研究通过人类组织推动「床旁到实验台再返回床旁」的转化研究,揭示心肌恢复通路并用于潜在治疗药物开发。
- 该领域正将从MCS心脏恢复研究环境中学到的经验扩展至更广泛而非终末期心力衰竭人群的治疗开发。
研究设计与样本
- 综述文章,聚焦MCS介导心肌恢复的生物学方面,并与聚焦临床方面的姊妹综述文章共同为临床医生和研究者提供框架。
主要发现
- 心脏重构涉及遗传、分子、细胞和组织水平的多种病理生理适应。
- 长期MCS在晚期心力衰竭儿童和成人患者中通过心室机械卸载和有效血流动力学支持实现心脏逆重构。
- MCS研究环境提供人类组织,可对心肌生物学及相关分子、细胞和结构恢复特征进行深入表征。
- 人类组织发现通过体外和体内小动物模型的敲除、抑制或过表达机制研究推动「床旁到实验台再返回床旁」方法。
- 这些转化和基础科学研究揭示心肌恢复机制通路,目前正进一步测试用于潜在治疗药物开发。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cardiac remodeling is an adaptive, compensatory biological process following an initial insult to the myocardium that gradually becomes maladaptive and causes clinical deterioration and chronic heart failure (HF). This biological process involves several pathophysiological adaptations at the genetic, molecular, cellular, and tissue levels. A growing body of clinical and translational investigations demonstrated that cardiac remodeling and chronic HF does not invariably result in a static, end-stage phenotype but can be at least partially reversed. One of the paradigms which shed some additional light on the breadth and limits of myocardial elasticity and plasticity is long term mechanical circulatory support (MCS) in advanced HF pediatric and adult patients. MCS by providing (a) ventricular mechanical unloading and (b) effective hemodynamic support to the periphery results in functional, structural, cellular and molecular changes, known as cardiac reverse remodeling. Herein, we analyze and synthesize the advances in our understanding of the biology of MCS-mediated reverse remodeling and myocardial recovery. The MCS investigational setting offers access to human tissue, providing an unparalleled opportunity in cardiovascular medicine to perform in-depth characterizations of myocardial biology and the associated molecular, cellular, and structural recovery signatures. These human tissue findings have triggered and effectively fueled a "bedside to bench and back" approach through a variety of knockout, inhibition or overexpression mechanistic investigations in vitro and in vivo using small animal models. These follow-up translational and basic science studies leveraging human tissue findings have unveiled mechanistic myocardial recovery pathways which are currently undergoing further testing for potential therapeutic drug development. Essentially, the field is advancing by extending the lessons learned from the MCS cardiac recovery investigational setting to develop therapies applicable to the greater, not end-stage, HF population. This review article focuses on the biological aspects of the MCS-mediated myocardial recovery and together with its companion review article, focused on the clinical aspects, they aim to provide a useful framework for clinicians and investigators.
引用
- Tseliou E, Lavine KJ, Wever-Pinzon O, et al. Biology of myocardial recovery in advanced heart failure with long-term mechanical support. J Heart Lung Transplant. 2022. PMID: 35965183. doi:10.1016/j.healun.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。